Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Kidney Int. 2019 Nov 26;97(4):753–764. doi: 10.1016/j.kint.2019.11.011

Figure 1: ZHX proteins in human glomerular disease.

Figure 1:

(a) Representative confocal images from MCD patients and control human kidney showing increased overlap (white arrows) of podocyte ZHX1 (red) with the podocyte nucleus (blue) in MCD patients. (b) Representative confocal images showing general reduction of ZHX2 expression in MCD glomeruli and absence of major changes in glomerular ZHX1 expression in FSGS. (c) Representative confocal images from FSGS patients and control human kidney showing increased overlap (white arrows) of podocyte ZHX2 and ZHX3 (both red) with the podocyte nucleus (blue) in FSGS patients. (d) Morphometric quantification of increased podocyte nuclear ZHX1 expression as a ZHX1:WT1 ratio in MCD patients represented in panel a. (e) Morphometric quantification of increased podocyte nuclear ZHX2 expression as ZHX2:WT1 ratio in FSGS patients shown in panel c. (f) Morphometric quantification of increased podocyte nuclear ZHX3 expression as ZHX3:WT1 ratio in FSGS patients represented in panel c. Scale bars: 9.5 μm (a, c top panels, panel b); 6.0 μm (a and c bottom panels). ** P < 0.01; *** P < 0.001.